Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aclaris Therapeutics Inc
ACRS | US
4.20
USD0.06
1.45%
ACRS | US
Loading StockChartView...
About Aclaris Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/04/2026
Close
4.20
Open
4.05
High
4.22
Low
4.01
Aclaris Therapeutics Inc. operates a clinical-stage biopharmaceutical company develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis and Hidradenitis suppurativa; and ATI-1777 a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138 an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231 an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics Inc. was incorporated in 2012 and is headquartered in Wayne Pennsylvania.
View LessACRS | US
Risk
79.6
Sharpe
1.80
Luna's Score
69/100
Recommendation
Buy
Luna says (ACRS | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
87.3%1 month
79.6%3 months
157.4%6 months
125.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.62
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
0.28
Ent. to rev.
35.36
PEG
-0.13
Other Fundamentals
EBITDA
-82.15M
MarketCap
299.65M
MarketCap(USD)
299.65M
Div. yield
-
Op. margin
-457.48
Erngs. growth
-
Rev. growth
48.00
Ret. on equity
-37.43
Short ratio
6.27
Short perc.
2.89
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.02
Range1M
1.30
Range3M
2.40
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.37
Price X volume
3.95M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.28 | 0.53 | Cheaper |
| Ent. to Revenue | 35.36 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.62 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 157.37 | 72.80 | Riskier |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 299.65M | 3.66B | Emerging |
